post

MEDIA STATEMENT: Carfilzomib approved for use in relapsed myeloma patients across Scotland

Press release // 7th August 2017

From today, myeloma patients in Scotland will be able to access new myeloma treatment, carfilzomib (Kyprolis®) on the NHS, after the Scottish Medicines Consortium (SMC) approved it for use.

The SMC, Scotland’s drug approval body, agreed that carfilzomib in combination with dexamethasone should be made available to myeloma patients who have received at least one prior treatment.

Myeloma is an incurable blood cancer originating in the bone marrow. Every year around 5,500 new cases are diagnosed in the UK of which 391¹ are diagnosed in Scotland.

This is great news for myeloma patients in Scotland. Today’s approval gives myeloma patients whose cancer has come back an important new treatment option.

Myeloma UK Policy and Public Affairs Officer Shelagh McKinlay

Myeloma UK Policy and Public Affairs Officer Shelagh McKinlay said, “This is great news for myeloma patients in Scotland. Today’s approval gives myeloma patients whose cancer has come back an important new treatment option. Having a range of effective options is especially vital in myeloma because it is such an individual cancer and becomes resistant to treatment.

“We played a key role in helping the SMC to reach its positive decision by ensuring that the patient and carer voice was heard in the process.”

Health Boards in Scotland now have three months to make a decision on whether to make carfilzomib available in this setting for patients in their local area.

Notes to Editors:

About Myeloma UK

Myeloma UK is the only organisation in the UK dealing exclusively with myeloma – our ultimate goal is to find a cure.

We are dedicated to ensuring that patients get access to the right treatment at the right time, and to improving standards of treatment and care through research, education and awareness raising.

Our organisation also provides a range of information and support services to patients, family and friends to help deal with a diagnosis of myeloma.

Myeloma UK receives no Government funding and relies almost entirely on voluntary donations and fundraising.

About myeloma

Myeloma is incurable but treatable blood cancer originating in the bone marrow.

The facts

  • Every year, around 5,500 people in the UK are diagnosed with myeloma
  • On average, 15 people are diagnosed with myeloma every day in the UK
  • ¹ In 2013, 4,703 cases were diagnosed in England, 391 in Scotland, 285 in Wales and 118 in Northern Ireland
  • Myeloma is a very individual cancer – no two myeloma patients are the same
  • Myeloma has been identified as having one of the highest rates of delay in diagnosis
  • 74% of people diagnosed with myeloma are aged 65 years and over